Total Prostate-Specific Antigen (Total PSA)
Serine protease (kallikrein-3) synthesized by prostatic epithelial cells to liquefy semen by cleaving semenogelins.
Standard vs. Optimal Reference Rangesng/mL
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
<4.0 ng/mL (age-adjusted: <2.5 in men <50 yrs)
General reference distribution across unselected commercial populations.
<1.5 ng/mL
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Secreted into seminal fluid; disruption of prostatic basement membrane architecture allows leakage into systemic circulation.
Differential Diagnosis
Elevated Levels (Total PSA High)
- •Prostate adenocarcinoma
- •Benign Prostatic Hyperplasia (BPH)
- •Acute or chronic bacterial prostatitis
- •Recent prostate biopsy or vigorous cycling
Low Levels (Total PSA Low)
- •Healthy quiescent prostate architecture (<1.5 ng/mL)
- •Complete post-radical prostatectomy nadir (<0.01 ng/mL)
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for Total PSA
- Targeted organ system imaging or functional dynamic testing related to prostatic kallikrein protease
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Total Prostate-Specific Antigen - The New England Journal of Medicine (2021). PMID: 34090124
- [2]Total PSA Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35322901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Total Prostate-Specific Antigen (Total PSA) into overall healthspan optimization.